NOT YET RECRUITING
NCT07946666
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Gender: All
Ages: 18 Years - 65 Years
Gastrointestinal Discomfort
Nausea
Bloating
+5